Safety Study of Combination Chemotherapy in Patients With Metastatic Solid Tumors or Adenocarcinoma of the Pancreas

Part of paid clinical trials in New York, New York.

Sponsor
St. Luke's-Roosevelt Hospital Center
Study ID
NCT00220649
Phase
PHASE1
Status
Completed

Conditions

  • Pancreatic Neoplasms

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this trial is to determine the maximum tolerated dose and the dose-limiting toxicity of biweekly oxaliplatin in combination with fixed doses of irinotecan, 5-fluorouracil/leucovorin and gemcitabine in patients with metastatic solid tumors or adenocarcinoma of the pancreas.

Key Dates

Start date
Mar 31, 2004
Status verified
Aug 2009

Study Design

Enrollment
25 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

To determine the maximum tolerated dose (MTD) and the dose-limiting toxicity (DLT) of biweekly oxaliplatin in combination with fixed doses of irinotecan, 5-fluorouracil/leucovorin and gemcitabine

Locations (1)

FacilityCityStateZIPSite coordinators
St. Luke's-Roosevelt Hospital CenterNew YorkNew York10019-

Find similar trials in New York, NY

By research site
St. Luke's-Roosevelt Hospital Center· New York, NY

Related Studies